8 results about "Erythrogenin" patented technology

To provide a novel erythropoietin production promoter.SOLUTION: An erythropoietin production promoter contains isorhamnetin and / or an isorhamnetin glycoside as an active ingredient.SELECTED DRAWING: Figure 1

The invention discloses a chlamydomonas reinhardtii source organism iron steady state regulator and application thereof, and belongs to the technical field of biology. The chlamydomonas reinhardtii hydroxyproline-rich glycoprotein or the protein component thereof disclosed by the invention can activate low-oxygen inducible factor signal channels of intestinal tracts, livers and kidneys, and up-regulate the expression of iron absorption transporters such as a divalent metal ion carrier 1, duodenum cytochrome b, membrane iron transporters and ferrous oxidase in intestinal epithelial cells; according to the present invention, the liver hepcidin overexpression caused by inflammation can be inhibited, the generation of erythropoietin in the liver and the kidney can be promoted so as to stimulate the absorption of the body on the iron nutrient, and the compound can be used in the anemia improving health food and the anemia improving drug. The organism iron homeostasis regulator adopted by the invention is derived from microalgae food, so that compared with a conventional artificially synthesized organism iron homeostasis regulator drug, the organism iron homeostasis regulator has the advantage of no toxic or side effect.

Compositions, methods, and uses are contemplated in which a betalain-containing preparation is administered to a mammal to enhance athletic performance. Most preferably, the preparations are substantially nitrate free and acutely and transiently increase hematocrit, erythropoietin, adrenalin, and beta endorphin, while reducing serum lactate, serum lactate dehydrogenase, heart rate and a rate of perceived exertion.

The present invention relates to a new variant of EPO. In this study, the inventors identified a particular EPO differing from kidney-type EPO due to a different glycosylation pattern in patients with different diseases (for example idiopathic erythrocytosis, liver / kidney disorder, tumors...). This new EPO is similar to pre-term newborn EPO produced by the liver that differs from the normal EPO produced from renal interstitial cells due to different post-translational modifications (glycosylations). This new EPO shows an increased biological activity via activation of the EPO receptor (EPOR), that can explain the origin of erythrocytosis. The detection of this specific liver-like EPO could be used as a diagnostic tool to better adapt and follow the treatments of erythrocytosis patients or in other diseases associated with the overproduction of red blood cells. Thus, the invention relates to a specific EPO protein which differs from the EPO with kidney-type glycosylation pattern.

The present invention relates to long-acting erythropoietin (EPO), an EPO mimetic peptide, and a use of the EPO.

Compositions, methods, and uses are contemplated in which a betalain-containing preparation is administered to a mammal to enhance athletic performance. Most preferably, the preparations are substantially nitrate free and acutely and transiently increase hematocrit, erythropoietin, adrenalin, and beta endorphin, while reducing serum lactate, serum lactate dehydrogenase, heart rate and a rate of perceived exertion.

The invention features polypeptides that include an extracellular ActRII variant, such as an ActRIIA variant, ActRIIB variant, or ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions that can be treated with erythropoietin or an erythropoiesis-stimulating agent.

The present invention relates to the fields of biotechnology and medicine and describes pharmaceutical compositions of recombinant human erythropoietin characterized by a microheterogeneity of fucosylated N-glycans formed by di-, tri-, and tetra-antennary structures with mono- and bi-sialylated sialic acid residues representing 40-60% of total glycans, tri-sialylated sialic acid residues representing 40-43% of total glycans, and tetra-sialylated sialic acid residues representing 10-13% of total glycans. This glycosylation pattern confers properties that allow the composition to be used in disorders of the nervous system. Methods for obtaining the pharmaceutical compositions described herein are also described.